Klaus Gellner

Title: Klaus Gellner: Innovator in Biotechnology

Introduction

Klaus Gellner is a notable inventor based in Peissenberg, Germany. He has made significant contributions to the field of biotechnology, particularly in the identification and characterization of gene families. His work has implications for drug development and therapeutic interventions.

Latest Patents

Klaus Gellner holds a patent for the identification of a new member of the cytochrome P450 3A (CYP3A) gene family, known as CYP3AX. This invention relates to polynucleotides encoding the CYP3AX protein and its variants. The patent also includes vectors that comprise these polynucleotides, which are operatively linked to regulatory elements for expression in prokaryotic and eukaryotic host cells. Furthermore, the invention encompasses proteins encoded by these polynucleotides and antibodies that specifically recognize such proteins. It also details methods for identifying drug candidates and inhibitors for disorders related to CYP3AX gene malfunctions, as well as diagnostic methods for such disorders. The patent provides pharmaceutical and diagnostic compositions that are particularly useful for treating diseases associated with CYP3AX genes.

Career Highlights

Klaus Gellner is associated with Epidauros Biotechnologie AG, where he continues to advance his research in biotechnology. His work has led to the development of innovative solutions in the field, contributing to the understanding of genetic functions and their applications in medicine.

Collaborations

Klaus has collaborated with notable colleagues, including Leszek Wojnowski and Regina Eiselt. These partnerships have fostered a collaborative environment that enhances research and innovation in biotechnology.

Conclusion

Klaus Gellner's contributions to biotechnology, particularly through his patent on CYP3AX, highlight his role as an innovator in the field. His work not only advances scientific knowledge but also has the potential to impact therapeutic practices significantly.